Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) have received an average rating of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $41.40.

COAG has been the topic of a number of research reports. Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. HC Wainwright initiated coverage on shares of Hemab Therapeutics in a research note on Wednesday, June 17th. They set a “buy” rating and a $40.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $39.00 price target for the company. Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Finally, The Goldman Sachs Group initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price target for the company.

Insider Transactions at Hemab Therapeutics

In other Hemab Therapeutics news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was bought at an average cost of $18.00 per share, with a total value of $48,150,000.00. Following the transaction, the director directly owned 6,149,096 shares in the company, valued at approximately $110,683,728. The trade was a 77.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have bought 2,970,541 shares of company stock worth $55,459,603.

Hemab Therapeutics Price Performance

Shares of COAG opened at $31.74 on Tuesday. Hemab Therapeutics has a 1-year low of $23.00 and a 1-year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.